Introduction
The O 6 -methylguanine-DNA methyltransferase (MGMT) gene encodes DNA repair protein and is frequently inactivated in colorectal cancer [1, 2] . Polymorphisms in MGMT have been associated with colorectal cancer risk [3, 4] , and MGMT promoter methylation in normal colonic mucosa might be a predisposing factor for cancer as a field effect and an early event in colorectal carcinogenesis [5, 6] . MGMT promoter methylation and loss of expression have been associated with G[A mutations in a variety of genes such as KRAS, PIK3CA, TP53, and APC [7] [8] [9] [10] [11] . Jass [12] proposed the molecular classification based on CIMP, MSI, BRAF, KRAS, and MGMT promoter methylation, indicating that MGMT methylation is one of the key molecular alterations in colorectal cancer. In addition, MGMT has potential as a therapeutic target in human cancer [13, 14] . Collectively, it is of interest to examine a prognostic role of MGMT alteration as a tumor biomarker. In brain tumors and B-cell lymphoma, MGMT methylation or loss of MGMT has been associated with poor prognosis [15] [16] [17] . However, prognostic significance of MGMT alteration in colorectal cancer remains inconclusive due to limited statistical power of all previous studies (Table 1 ; all n \ 200) [18] [19] [20] [21] [22] .
In this study using the database of a large number (n = 855) of stage I-IV colorectal cancers, we examined the prognostic effect of MGMT promoter methylation and loss of expression. Since we concurrently assessed other molecular variables including LINE-1 hypomethylation, MSI, CIMP, and mutation in KRAS, BRAF, and PIK3CA, we could evaluate the prognostic effect of MGMT alteration after controlling for those potential confounders.
Materials and methods

Study population
We utilized the database of two prospective cohort studies, the Nurses' Health Study (n = 121,701 women followed since 1976) [23] and the Health Professionals Follow-up Study (n = 51,529 men followed since 1986) [23] . Par Pyrosequencing of KRAS, BRAF, and PIK3CA, and microsatellite instability (MSI) analysis Genomic DNA was extracted from paraffin-embedded tissue. PCR and pyrosequencing targeted for KRAS (codons 12 and 13) [24] , BRAF (codon 600) [25] , and PIK3CA (exons 9 and 20) [11] were performed. Microsatellite instability (MSI) analysis was performed using 10 microsatellite markers (D2S123, D5S346, D17S250, BAT25, BAT26, BAT40, D18S55, D18S56, D18S67, and D18S487) [26] . MSI-high was defined as the presence of instability in C30% of the markers and MSI-low/microsatellite stable (MSS) as instability in 0-29% of markers [26] .
Methylation analyses for CpG islands and LINE-1
Sodium bisulfite treatment and subsequent real-time PCR were performed to quantify promoter methylation in MGMT and eight other CpG islands (CACNA1G, CDKN2A, CRABP1, IGF2, MLH1, NEUROG1, RUNX3, and SOCS1) [27, 28] ; the latter eight markers have been shown to be specific for CIMP [29] . CIMP-high was defined as the presence of C6/8 methylated markers, CIMP-low as the presence of 1/8-5/8 methylated markers, and CIMP-0 as the absence (0/8) of methylated markers [30] . We defined and validated the cut point for MGMT promoter methylation positivity (percentage of methylated reference, or PMR[ 4) as previously described [31] . LINE-1 methylation levels were quantified by PCR-pyrosequencing [32, 33] .
Immunohistochemical analysis
Immunohistochemical methods for MGMT and TP53 (p53) were previously described [26] , and expression patterns were interpreted by a pathologist (S.O.) unaware of other data. In agreement studies, a random selection of more than 100 cases for each marker was interpreted by a second pathologist unaware of other data (MGMT by K.S.; TP53 by K.N.). The concordance between the two observers (both p \ 0.0001) was 0.86 for MGMT (j = 0.70) and 0.87 for TP53 (j = 0.75), indicating substantial agreement. The concordance between MGMT methylation and loss of MGMT was 81% (j = 0.59).
Statistical analysis
We used SAS program (Version 9.1, SAS Institute, Cary, NC) for all statistical analysis. All p values were two-sided, and significance level was set at p = 0.05. The chi-square test (or Fisher's exact test) was performed for categorical variables. For survival analysis, the Kaplan-Meier method and log-rank test were used. For analyses of colorectal cancer-specific mortality, deaths as a result of causes other than colorectal cancer were censored. To control for confounding, we used multivariate stage-matched (stratified) Cox proportional hazard models to compute hazard ratio ( , we included those cases in a majority category of a given covariate to avoid overfitting. We confirmed that excluding cases with missing information in any of the covariates did not substantially alter results (data not shown). An interaction was assessed by including the cross product of the MGMT methylation (or MGMT loss) variable and another variable of interest (without data-missing cases) in a multivariate model, and the Wald test was performed. A p value for statistical significance was adjusted for multiple hypothesis testing to p = 0.0029 (=0.05/17) by Bonferroni correction.
In addition, we constructed multivariate logistic regression analysis model to assess the independent effect of MGMT loss on G[A mutations in KRAS or PIK3CA (as a binary outcome variable). The model initially included age at diagnosis (continuous), sex, year of diagnosis (continuous), BMI (\30 vs. C30 kg/m 2 ), family history of colorectal cancer (present vs. absent), tumor location (proximal vs. distal), MSI (high vs. low/MSS), CIMP (high vs. low/0), LINE-1 methylation (continuous), and MGMT loss, and a backward elimination with a threshold of p = 0.20 was done to select variables in the final model.
Results
MGMT methylation and loss of MGMT in colorectal cancer
MGMT promoter methylation was detected in 325 (38%) of 885 tumors, and loss of MGMT was detected in 247 (37%) of 672 tumors. There was a significant association between MGMT promoter methylation and CIMP status (p \ 0.0001). Loss of MGMT was significantly associated with PIK3CA mutation (p = 0.0031) and inversely associated with TP53 expression (p = 0.0004; Table 2 ).
MGMT methylation/loss and G[A mutations in KRAS and PIK3CA
Because functional loss of MGMT may contribute to G[A mutations [7] [8] [9] [10] [11] , we examined the relations between MGMT methylation (or loss) and G[A mutations in KRAS and PIK3CA (Table 2) . MGMT loss was significantly associated with G[A mutations in KRAS (p = 0.019) and PIK3CA (p = 0.0031) (by a priori hypothesis testing), while MGMT methylation was not. In multivariate logistic regression analysis to assess independent effect of MGMT loss on G[A mutations, MGMT loss remained significantly associated with G[A mutations in KRAS (adjusted OR, 1.58; 95% CI, 1.07-2.34; p = 0.021) and PIK3CA (adjusted OR, 2.55; 95% CI, 1.40-4.68; p = 0.0024).
MGMT methylation, loss of MGMT, and survival of patients with colorectal cancer Among the 855 patients, there were 415 deaths including 234 colorectal cancer-specific deaths. The median followup time for censored patients was 13.0 years. For either colorectal cancer-specific or overall mortality, MGMT methylation was not significantly associated with patient outcome in log-rank test, or univariate or multivariate stage-matched Cox regression analysis (Table 3 , Fig. 1) . Likewise, loss of MGMT was not significantly associated with colorectal cancer-specific or overall mortality in univariate or multivariate stage-matched analysis (Table 3 , Fig. 1) .
We analyzed the prognostic effect of MGMT methylation or loss of MGMT in colon cancer and rectal cancer separately, since clinical management for patients with colon cancer differ from that for patients with rectal cancer. MGMT methylation (or MGMT loss) was not significantly associated with colorectal cancer-specific or overall mortality in either patients with colon cancer or rectal cancer (Table 3) .
There was no significant modifying effect on the prognostic influence of MGMT methylation (or MGMT loss) by 
Discussion
We conducted this study to examine whether MGMT promoter methylation or loss of expression in colorectal cancer has any prognostic role. This question has remained inconclusive due to limited statistical power of all previous studies on this topic [18] [19] [20] [21] [22] . Given the crucial roles of MGMT aberrations in colorectal carcinogenesis or a potential use of MGMT as a therapeutic target in human cancer, the assessment of MGMT alteration (i.e., MGMT promoter methylation or loss of MGMT) and clinical outcome using a large number of cancers is needed. Utilizing the database of 855 clinically and molecularly annotated colorectal cancers in the two large prospective cohort studies, we found that MGMT alteration was not associated The multivariate, stage-matched (stratified) Cox regression model initially included the MGMT promoter methylation or loss of MGMT variable, sex, age at diagnosis, year of diagnosis, tumor location, obesity, family history of colorectal cancer, tumor grade, CIMP, MSI, BRAF, and LINE-1 methylation. A backward elimination with threshold of p = 0.20 was used to select variables in the final models. CI confidence interval, HR hazard ratio with patient prognosis in colorectal cancer. In addition, we assessed the prognostic effect of MGMT promoter methylation (or MGMT loss), controlling for other molecular features, including CIMP, MSI, and BRAF mutation, all of which have been documented to be critical in colorectal carcinogenesis. Studying molecular variants and somatic changes is important in cancer research [34] [35] [36] [37] [38] [39] [40] [41] [42] . Recent studies have shown that MGMT promoter polymorphism (rs16906252) is associated with MGMT methylation in colorectal cancer [43] , in normal colorectal mucosa [44] , and in peripheral blood cells from normal individuals [45] . Epigenetic silencing of MGMT by promoter methylation in normal colonic mucosa may be a predisposing factor for cancer as a field effect and an early event in colorectal carcinogenesis [5, 6] . In addition, MGMT methylation might be a valuable biomarker in plasma for early detection of colorectal cancer [46] . Studies on colorectal cancer have shown that MGMT methylation is associated with MGMT loss [5, 6, 47] . In agreement with these studies [5, 6, 47] , our current study showed a good concordance (81%, j = 0.59, p \ 0.0001) between MGMT methylation and MGMT loss. MGMT methylation and loss of MGMT were not perfectly correlated perhaps due to a few reasons. First, loss of MGMT expression may be caused not only by promoter methylation but also by other mechanisms such as a gene deletion or mutation. Second, in rare cases, promoter methylation may be present in only one MGMT allele, and the MGMT protein may be expressed from the second allele. Third, there may be other molecules (such as miRNA) that may downregulate MGMT.
MGMT promoter methylation or loss of expression in colorectal cancer has been associated with G[A mutations in KRAS [7, 9, 10, 44, 48] , TP53 [8, 9] , and PIK3CA [11] . Our current study is the first one to perform multivariate analysis and show that MGMT loss is associated with G[A mutations in KRAS and PIK3CA, independent of potential confounders. Thus, our current study supports the concept that loss of MGMT contributes to G[A mutations of KRAS and PIK3CA.
Previous studies [18] [19] [20] [21] [22] have shown no prognostic significance of MGMT methylation (or loss of MGMT) in colorectal cancers (Table 1) . These previous studies [18] [19] [20] [21] [22] on prognostic significance of MGMT methylation (or MGMT loss) are limited by low statistical power (n \ 200). In contrast to the prior studies [18] [19] [20] [21] [22] , our study examined both MGMT promoter methylation and loss of MGMT expression in a much larger cohort of colorectal cancers. In the current study, MGMT methylation was found in 38% of colorectal cancer. Previous studies [18] [19] [20] [21] [22] have shown a large variation in the frequency of MGMT promoter methylation (21-61%; Table 1 ). This variation might be caused by differences in study samples and/or methylation detection methods (MSP vs. quantitative MethyLight vs. Pyrosequencing) and might also be in part due to a chance variation in the small studies.
With regard to the predictive role of MGMT aberrations, Braun et al. [34] examined a predictive role of loss of MGMT expression (among other markers) in 1,125 patients with metastatic colorectal cancer who underwent different chemotherapy treatment arms (fluorouracil vs. fluorouracil/irinotecan vs. fluorouracil/oxaliplatin) and found no predictive role of MGMT aberrations.
There are limitations in this study. For example, data on cancer treatment were limited. Nonetheless, it is unlikely that chemotherapy use substantially differed according to MGMT status in tumor, since such data were unavailable for treatment decision making. In addition, our multivariate survival analysis adjusted for disease stage as finely as I, IIA, IIB, IIIA, IIIB, IIIC, IV on which treatment decision making was mostly based. As another limitation, beyond cause of mortality, data on cancer recurrences were unavailable in these cohort studies. Nonetheless, colorectal cancer-specific survival might be a reasonable surrogate of colorectal cancer-specific outcome.
There are advantages in utilizing the database of the two prospective cohort studies, the Nurses' Health Study and the Health Professionals Follow-up Study, to examine prognostic significance of tumor biomarkers. Anthropometric measurements, family history, cancer staging, and other clinical, pathologic, and tumoral molecular data were prospectively collected, blinded to patient outcome. Cohort participants who developed cancer were treated at hospitals throughout the United States and thus more representative colorectal cancers in the US population than patients in one to a few academic hospitals. There were no demographic difference between cases with tumor tissue analyzed and those without tumor tissue analyzed [23] . Finally, our rich tumor database enabled us to simultaneously assess pathologic and tumoral molecular correlates and control for confounding by a number of tumoral molecular alterations.
In conclusion, our findings suggest that MGMT promoter methylation or loss of expression is not a prognostic biomarker in colorectal cancer, despite its well-established role in carcinogenesis.
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